NasdaqGM - Delayed Quote • USD
KalVista Pharmaceuticals, Inc. (KALV)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 3 | 5 | 5 |
| Avg. Estimate | -0.71 | -0.67 | -3.03 | -2.39 |
| Low Estimate | -0.79 | -0.73 | -3.16 | -2.83 |
| High Estimate | -0.55 | -0.57 | -2.84 | -1.71 |
| Year Ago EPS | -0.77 | -0.74 | -3.33 | -3.03 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 3 | 5 | 4 |
| Avg. Estimate | -- | -- | -- | 20.61M |
| Low Estimate | -- | -- | -- | 12.76M |
| High Estimate | -- | -- | -- | 35.51M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 4/30/2023 | 7/31/2023 | 10/31/2023 | 1/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.94 | -0.86 | -0.79 | -0.77 |
| EPS Actual | -0.77 | -0.74 | -0.8 | -0.84 |
| Difference | 0.17 | 0.12 | -0.01 | -0.07 |
| Surprise % | 18.10% | 14.00% | -1.30% | -9.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.71 | -0.67 | -3.03 | -2.39 |
| 7 Days Ago | -0.71 | -0.65 | -3.03 | -2.44 |
| 30 Days Ago | -0.71 | -0.65 | -3.03 | -2.44 |
| 60 Days Ago | -0.75 | -0.65 | -3.03 | -2.63 |
| 90 Days Ago | -0.66 | -0.74 | -2.92 | -2.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | KALV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 7.80% | -- | -- | 6.50% |
| Next Qtr. | 9.50% | -- | -- | 12.00% |
| Current Year | 9.00% | -- | -- | 5.30% |
| Next Year | 21.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/12/2024 |
| Maintains | Needham: Buy to Buy | 3/11/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/14/2024 |
| Maintains | Needham: Buy to Buy | 2/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/8/2023 |
Related Tickers
PHVS Pharvaris N.V.
23.35
+2.55%
ENTA Enanta Pharmaceuticals, Inc.
12.37
-0.88%
PCVX Vaxcyte, Inc.
60.72
+1.10%
PRAX Praxis Precision Medicines, Inc.
54.80
+3.63%
KURA Kura Oncology, Inc.
19.65
+3.42%
REPL Replimune Group, Inc.
6.42
+4.39%
IMVT Immunovant, Inc.
27.17
-2.09%
MGTX MeiraGTx Holdings plc
4.8000
+1.91%
IGMS IGM Biosciences, Inc.
9.40
+22.88%
PHAT Phathom Pharmaceuticals, Inc.
9.18
+0.88%